RE: Data read out Q2 202428 Feb 2024 20:22
Significant Newsflow
The Company is anticipating the progression of its clinical development and research stage programmes to important value inflection points across 2024 and 2025, which includes key deliverables for the pre|CISIONTM pipeline:
· AVA6000:
o Read out of two-weekly and three-weekly dose escalation study data in late Q2 2024;
o Presentation of Phase 1 three-weekly study clinical data at AACR 2024 in April 2024; and
o Establish recommended Phase 2 dose in Q3 2024, initiating the dose expansion phase in the US in H2 2024, followed by the Phase 2 study, subject to funding and FDA approval.